Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent LeasesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Mirum Pharmaceuticals (MIRM) Other Non-Current Liabilities: 2020-2024

Historic Other Non-Current Liabilities for Mirum Pharmaceuticals (MIRM) over the last 5 years, with Dec 2024 value amounting to $2.5 million.

  • Mirum Pharmaceuticals' Other Non-Current Liabilities rose 302.34% to $16.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $16.0 million, marking a year-over-year increase of 302.34%. This contributed to the annual value of $2.5 million for FY2024, which is 34.81% down from last year.
  • Mirum Pharmaceuticals' Other Non-Current Liabilities amounted to $2.5 million in FY2024, which was down 34.81% from $3.8 million recorded in FY2023.
  • Over the past 5 years, Mirum Pharmaceuticals' Other Non-Current Liabilities peaked at $140.4 million during FY2022, and registered a low of $2.5 million during FY2024.
  • For the 3-year period, Mirum Pharmaceuticals' Other Non-Current Liabilities averaged around $48.9 million, with its median value being $3.8 million (2023).
  • In the last 5 years, Mirum Pharmaceuticals' Other Non-Current Liabilities soared by 172.66% in 2021 and then tumbled by 97.26% in 2023.
  • Yearly analysis of 5 years shows Mirum Pharmaceuticals' Other Non-Current Liabilities stood at $47.7 million in 2020, then soared by 172.66% to $129.9 million in 2021, then rose by 8.03% to $140.4 million in 2022, then plummeted by 97.26% to $3.8 million in 2023, then plummeted by 34.81% to $2.5 million in 2024.